Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (51-60 of 134) with videos related to

Pageof 14
Sort By:
Gynecologic Oncology|July 13, 2007
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancerGraeme Walker, Kenneth MacLeod, Alistair R W Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancerGraeme Walker, Kenneth MacLeod, Alistair R W Williams, et al.
Investigative Ophthalmology & Visual Science|May 2, 2009
Light responses in rods of vitamin A-deprived XenopusEduardo Solessio, Yumiko Umino, David A Cameron, et al.
Lancet (London, England)|February 17, 2020
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' replyHelena M Earl, Louise Hiller, Chris Plummer, et al.
The Journal of the Acoustical Society of America|December 31, 2024
Profile analysis in listeners with normal and elevated audiometric thresholds: Behavioral and modeling resultsDaniel R Guest, David A Cameron, Douglas M Schwarz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01Ruth E Langley, James Carmichael, Alison L Jones, et al.
Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.
Breast Cancer Research and Treatment|September 18, 2022
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional studyAnushri Chitkara, Ines Mesa-Eguiagaray, Sarah H Wild, et al.
Endocrine-Related Cancer|December 13, 2006
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer modelsBarbara Kuske, Catherine Naughton, Kate Moore, et al.
Breast Cancer Research and Treatment|January 20, 2016
Characterizing and quantifying the effects of breast cancer therapy using mathematical modelingWalter M Gregory, Christopher J Twelves, Richard Bell, et al.
Pageof 14

Showing results (51-60 of 134) with videos related to

Sort By:
Pageof 14
Gynecologic Oncology|July 13, 2007
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancerGraeme Walker, Kenneth MacLeod, Alistair R W Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancerGraeme Walker, Kenneth MacLeod, Alistair R W Williams, et al.
Investigative Ophthalmology & Visual Science|May 2, 2009
Light responses in rods of vitamin A-deprived XenopusEduardo Solessio, Yumiko Umino, David A Cameron, et al.
Lancet (London, England)|February 17, 2020
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' replyHelena M Earl, Louise Hiller, Chris Plummer, et al.
The Journal of the Acoustical Society of America|December 31, 2024
Profile analysis in listeners with normal and elevated audiometric thresholds: Behavioral and modeling resultsDaniel R Guest, David A Cameron, Douglas M Schwarz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01Ruth E Langley, James Carmichael, Alison L Jones, et al.
Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.
Breast Cancer Research and Treatment|September 18, 2022
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional studyAnushri Chitkara, Ines Mesa-Eguiagaray, Sarah H Wild, et al.
Endocrine-Related Cancer|December 13, 2006
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer modelsBarbara Kuske, Catherine Naughton, Kate Moore, et al.
Breast Cancer Research and Treatment|January 20, 2016
Characterizing and quantifying the effects of breast cancer therapy using mathematical modelingWalter M Gregory, Christopher J Twelves, Richard Bell, et al.
Pageof 14